Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Table_1_Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile.docx by Xiaoyu Ding (391861)

Table_2_Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile.docx by Xiaoyu Ding (391861)

Table_3_Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile.docx by Xiaoyu Ding (391861)

Short-term/immediate adverse outcomes of neonatal birth trauma. by Beshada Zerfu Woldegeorgis (12916598)

Indicators for competitive comparative advantage and their significance. by Linhan Shao (20978182)

Subjects:

Distribution of cases and adverse events associated with metformin. by Mengsi Peng (12882734)

Subjects:

Association between GWG and adverse neonatal outcomes in parity subpopulations. by Feifei Jiang (11795243)

Subjects:

Cases based on number of DG allocation units. by Zeeshan Memon Anjum (12413383)

Subjects:

Deterministic result of the base-case analysis. by Sudewi Mukaromah Khoirunnisa (15288505)

“…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …”

Base-case estimated number of patients categorised in different phenotypes and age groups and their base-case cost of management. by Siew Chin Ong (9314213)

Base-case results based on evidence from randomized controlled trials (means and ranges). The comparator is no intervention. by Afschin Gandjour (342184)

Base-case results (deterministic analysis). by Robert Hodgson (2026294)

Base-case results: Probabilistic analysis. by Robert Hodgson (2026294)

Effect of interventions on clinical outcomes (ICU admission rate, adverse events, mortality, readmission or return visit to a health facility, recurrence of infection, and treatmen... by Jessica Craig (409538)

Base-case results. by Ping Chen (89712)

The base case analysis. by Wenwang Lang (20293527)

“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”

Top contributor of tissues of significant genes for AD. By ranking tissues based on their loadings in matrix <i>T</i>, we identified which tissues are the top contributors to signi... by Yan Yan (208529)

Base-case results. by Shuo Kang (1306860)

“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”

Multivariable logistic analysis showing significant indicators and their odds ratios of dengue positivity in the health facility-based fever surveillance. by Jacqueline Kyungah Lim (10125351)